Metastatic renal cell carcinoma (mRCC)

SUTENT® (sunitinib malate) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (mRCC) in adults.1

1. SUTENT® Summary of Product Characteristics. Pfizer. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info...
Accessed: May 2018. PP-SUT-GBR-0305. June 2018